**A Pubmed literature search and Deciphera Publications from 2019-2021 are listed below:**

**Pubmed Search**

1: Dhillon S. Ripretinib: First Approval. Drugs. 2020 Jul;80(11):1133-1138. doi: 10.1007/s40265-020-01348-2. Erratum in: Drugs. 2020 Dec;80(18):1999. PMID: 32578014; PMCID: PMC7595980.

2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Ripretinib. 2021 Jan 18. PMID: 33226755.

3: Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498. doi: 10.1177/1758835920986498. PMID: 33473249; PMCID: PMC7797597.

4: Florou V, Trent JC, Wilky BA. Precision medicine in gastrointestinal stromal tumors. Discov Med. 2019 Nov-Dec;28(155):267-276. PMID: 32053767.

5: Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020 Apr 16;135(16):1365-1376. doi: 10.1182/blood.2019000932. PMID: 32106312.

6: Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tumours. Curr Opin Oncol. 2019 Jul;31(4):322-328. doi:10.1097/CCO.0000000000000549. PMID: 31033566.

7: Serrano C, George S. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clin Cancer Res. 2020 Oct 1;26(19):5078-5085. doi: 10.1158/1078-0432.CCR-20-1706. Epub 2020 Jun 29. PMID: 32601076.

8: Farag S, Smith MJ, Fotiadis N, Constantinidou A, Jones RL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol. 2020 May 27;21(7):55. doi: 10.1007/s11864-020-00754-8. PMID: 32462367; PMCID: PMC7253383.

9: Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019 May 17;11:1758835919841946. doi: 10.1177/1758835919841946. PMID: 31205499; PMCID: PMC6535752.

10: Martin-Broto J, Moura DS. New drugs in gastrointestinal stromal tumors. Curr Opin Oncol. 2020 Jul;32(4):314-320. doi: 10.1097/CCO.0000000000000642. PMID: 32541319.

11: Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021 Jan 5;14(1):2. doi: 10.1186/s13045-020-01026-6. PMID: 33402214; PMCID: PMC7786896.

12: Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, Theocharis S, Papavassiliou AG, Karamouzis MV. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. Int J Mol Sci. 2021 Jan 6;22(2):493. doi: 10.3390/ijms22020493. PMID: 33419029; PMCID: PMC7825300.

13: Mohammadi M, Gelderblom H. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Expert Opin Investig Drugs. 2021 Feb;30(2):143-152. doi: 10.1080/13543784.2021.1857363. Epub 2020 Dec 3. PMID: 33252274.

14: Italiano A. New insights into the clinical management of advanced gastrointestinal stromal tumors. Expert Opin Pharmacother. 2021 Mar;22(4):439-447. doi: 10.1080/14656566.2020.1828346. Epub 2020 Dec 14. PMID: 33307872.

15: Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021 Mar 18;7(1):22. doi: 10.1038/s41572-021-00254-5. PMID: 33737510.

16: Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26. PMID: 33513356.

17: Yonkus JA, Alva-Ruiz R, Grotz TE. Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Curr Treat Options Oncol. 2021 Mar 20;22(5):37. doi: 10.1007/s11864-021-00837-0. PMID: 33743084.

18: Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF, Philip PA. Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer Metastasis Rev. 2021 Apr 19. doi: 10.1007/s10555-021-09961-7. Epub ahead of print. PMID: 33876372.

19: Shomali W, Gotlib J. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. Int J Mol Sci. 2021 Mar 15;22(6):2983. doi: 10.3390/ijms22062983. PMID: 33804174; PMCID: PMC8001403.

**Deciphera Publications (2019-2021)**

1.George S, Janku F, Chi P. et al. Population pharmacokinetics of ripretinib in patients with advanced malignancies. Poster presented at the AACR Virtual Annual Meeting 2021, April 10–15.

2. Li X, Shelton MJ, Meade J, et al. Effect of gastric acid reduction and strong CYP3A induction/inhibition on the pharmacokinetics of ripretinib, a switch control tyrosine kinase inhibitor. Poster presented at the AACR Virtual Annual Meeting 2021, April 10–15.

3. George S, Heinrich MC, Zalcberg J, et al. Safety profile of ripretinib, including impact of alopecia and palmar plantar erythrodysesthesia syndrome (PPES) on patient reported outcomes (PROs), in ≥4th line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Poster presented at the ASCO Annual Virtual Meeting, May 29-31, 2020.

4. Heinrich MC, George S, Zalcberg J, et al. Quality of life (QoL) and self reported function with ripretinib in ≥4th line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Poster presented at the ASCO Annual Virtual Meeting, May 29-31, 2020.

5. Blay J-Y, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923-934.

6. Serrano C, Heinrich MC, George S, et al. Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor (GIST) following crossover from placebo: Analyses from INVICTUS. Oral presentation at ESMO World Congress on Gastrointestinal Cancer virtual meeting, 2020.

7. Zalcberg J, Heinrich MC, George S, et al. Clinical Benefit with Ripretinib as ≥4th Line Treatment in Patients with Advanced Gastrointestinal Stromal Tumors (GIST): Update from the Phase 3 INVICTUS Study. Oral presentation at ESMO Virtual Congress, September 19-21, 2020.

8. Janku F, Chi P, Heinrich MC, et al. Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase 1 study. Oral presentation at Virtual ESMO congress. September 19-21, 2020.

9. Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: A phase I study of ripretinib. J Clin Oncol. 2020;32(28):3294-3303.

10. Schöffski P, Bauer S, Heinrich M, et al. Ripretinib demonstrated activity across all KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Analysis from the phase 3 INVICTUS study. Poster presented at CTOS Virtual Meeting; November 18-21, 2020.

11. Bauer S, Schöffski P, Heinrich M, et al. Characterization of the extensive heterogeneity of KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Genomic analysis of the phase 3 INVICTUS study. Oral presentation at CTOS Virtual Meeting; November 18-21, 2020.

12. Janku F, Heinrich M, Chi P, et al. Ripretinib (DCC-2618) pharmacokinetics (PK) in a phase 1 study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: a retrospective evaluation of the PK effects of proton pump inhibitors (PPIs). Poster presented at the American Association for Cancer Research (AACR) annual meeting, March 29-April 3, 2019; Atlanta, Georgia.

13. von Mehren V, Bauer S, George S, et al. INVICTUS: A phase 3, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥4th line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). Oral presentation at ESMO Congress, September 27-October 1 2019; Barcelona, Spain.

14. Chi P, Janku F, Heinrich M, et al. Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036). Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. October 26-30, 2019; Boston, MA.

15. Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738-751.

16. Nemunaitis J, Bauer S, Blay J-Y, et al. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol. 2019;16(1):4251-4264.

17. Zalcberg JR. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Ther Adv Gastroenterol. 2021;14:1-12 (ahead of print). DOI: 10.1177/17562848211008177